Eco R1 Capital, LLC T Scan Therapeutics, Inc. Call Options Transaction History
Eco R1 Capital, LLC
- $3.51 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TCRX
# of Institutions
67Shares Held
29.3MCall Options Held
0Put Options Held
0-
Adage Capital Partners Gp, L.L.C. Boston, MA3.9MShares$22.3 Million0.06% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$17.1 Million0.71% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$15.9 Million0.28% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$11.9 Million9.65% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.81MShares$10.3 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $108M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...